LUCILLE VON ROEMER: Open Payments
NPI 1700573128 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,389 in 58 payments from 14 companies in 2025. Trend: 2023 $310 · 2024 $1,134 · 2025 $1,389
Food & beverage: $1,389
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 11 | $417 |
| ABBVIE INC. | 23 | $382 |
| Gilead Sciences, Inc. | 4 | $175 |
| VIVUS LLC | 3 | $65 |
| Lilly USA, LLC | 3 | $62 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $56 |
| Novo Nordisk Inc | 2 | $43 |
| Aimmune Therapeutics, Inc. | 2 | $42 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $34 |
| Phathom Pharmaceuticals, Inc. | 2 | $33 |
Products named: REZDIFFRA, RINVOQ, SKYRIZI, CREON, OMVOH, XIFAXAN, PANCREAZE, Wegovy.
Industry payments across GA — which companies pay providers there.
